Galectin Therapeutics Inc (GALT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.98-13.98%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · GALT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Importantly, we reached an agreement with the FDA on the key elements of our planned Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension and aligned on the regulatory path forward.
Stated in 2 of 2 supplied quarters. Management reported: “Importantly, we reached an agreement with the FDA on the key elements of our planned Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension and aligned on the regulatory path forward.” “The Company believes it has sufficient cash to fund currently planned operations and research and development activities through June 2027.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Importantly, we reached an agreement with the FDA on the key elements of our planned Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension and aligned on the regulatory path forward.”
““We continue to make meaningful progress advancing the belapectin program and further analyzing the NAVIGATE dataset in patients with MASH cirrhosis and portal hypertension.”
The Company believes it has sufficient cash to fund currently planned operations and research and development activities through June 2027.
Stated in 2 of 2 supplied quarters. Management reported: “The Company believes it has sufficient cash to fund currently planned operations and research and development activities through June 2027.” “Additionally, the Company has $10 million remaining available under a line of credit provided by its Chairman of the Board to fund operations.”
“The Company believes it has sufficient cash to fund currently planned operations and research and development activities through June 2027.”
“The Company believes it has sufficient cash to fund currently planned operations and research and development activities through May 2027.”
The transaction simplifies Galectin’s capital structure and strengthens its balance sheet.
Stated in 1 of 2 supplied quarters. Management reported: “The transaction simplifies Galectin’s capital structure and strengthens its balance sheet.” “Uihlein, the Company’s Chairman of the Board and largest stockholder, has converted all outstanding principal and accrued interest under five of the Company’s line of credit facilities into shares of the Company’s common stock, effective July 31, 2026.”
“The transaction simplifies Galectin’s capital structure and strengthens its balance sheet.”
Present new analyses from NAVIGATE trial and publish manuscripts to support belapectin's clinical profile.
Access a $10 million line of credit to finance working capital needs.
Over the trailing year it converted 0.78x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
7 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.